Kuo transitioned from securing a substantial grant in 2021 to scaling Wobble Genomics from 2 to 16 employees, ultimately raising £8.5 million in 2024.
The collapse of Theranos has created a more challenging funding landscape for biotech startups, raising concerns among entrepreneurs about investor confidence and future opportunities.
Kuo's beginnings in entrepreneurship were shaped by a successful competition project aimed at aiding the visually impaired, sparking his interest in commercializing biotech innovations.
Moving from stealth mode to public operations signifies Wobble's readiness to engage with the market, indicating a pivotal shift in strategy and long-term business vision.
Collection
[
|
...
]